FDA approved AstraZeneca’s Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
FDA Approves AstraZeneca’s Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
